Certara (NASDAQ:CERT) Shares Gap Up - Here's What Happened

Certara, Inc. (NASDAQ:CERT - Get Free Report)'s share price gapped up before the market opened on Tuesday . The stock had previously closed at $11.00, but opened at $11.45. Certara shares last traded at $10.96, with a volume of 153,781 shares traded.

Analyst Ratings Changes

A number of research analysts have issued reports on CERT shares. Robert W. Baird upped their target price on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, April 11th. TD Cowen assumed coverage on shares of Certara in a research note on Thursday, February 27th. They issued a "buy" rating and a $16.00 target price for the company. JMP Securities reissued a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $11.00 to $14.00 in a report on Thursday, May 8th. Finally, William Blair reiterated a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $15.67.

Certara Stock Up 0.5%

The firm has a market capitalization of $1.91 billion, a PE ratio of -58.80, a price-to-earnings-growth ratio of 9.29 and a beta of 1.44. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm has a 50-day moving average of $11.98 and a two-hundred day moving average of $11.82.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. During the same period last year, the business posted $0.10 EPS. The company's quarterly revenue was up 9.7% compared to the same quarter last year. On average, equities research analysts forecast that Certara, Inc. will post 0.28 EPS for the current year.

Institutional Investors Weigh In On Certara

Large investors have recently made changes to their positions in the business. Jane Street Group LLC boosted its position in Certara by 17.1% during the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company's stock worth $2,743,000 after purchasing an additional 40,463 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company's stock valued at $2,965,000 after buying an additional 35,954 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Certara by 65.6% during the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company's stock worth $2,267,000 after purchasing an additional 90,724 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Certara in the first quarter worth about $297,000. Finally, Select Equity Group L.P. increased its holdings in shares of Certara by 534.5% in the 1st quarter. Select Equity Group L.P. now owns 1,094,495 shares of the company's stock valued at $10,836,000 after acquiring an additional 922,007 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.